- Supported exchanges /
- NASDAQ /
- DRMAW.NASDAQ
Dermata Therapeutics Inc. Warrant (DRMAW NASDAQ) stock market data APIs
Dermata Therapeutics, Inc., a late-stage medical dermatology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions and diseases. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe acne; and Phase Ib proof of concept (POC) trial for Mild-to-Moderate Psoriasis, as well as is in a Phase 2 clinical trial for treatment of moderate-to-severe rosacea. It is also developing DMT410 that has completed Phase Ib POC trials for the treatment of anxillary hyperhidrosis and aesthetic conditions. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Dermata Therapeutics Inc. Warrant Financial Data Overview
| 0.0098 | |
| 0.0098 | |
| - | |
| 0.0098 | |
| 0.0098 | |
| 0.007-0.0262 | |
| 0 | |
| 0 | |
| 0 | |
| 0.778 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Dermata Therapeutics Inc. Warrant Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -4 085 968
- Earnings Per Share -2.156
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Dermata Therapeutics Inc. Warrant Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get Dermata Therapeutics Inc. Warrant End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
